Mereo BioPharma Group plc - Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares (MREO)

Historical Holders from Q2 2019 to Q3 2025

Symbol
MREO on Nasdaq
CUSIP
589492107
Type / Class
Equity / Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares
Shares outstanding
791M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
98.6M
Holdings value
$267M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
83
Number of buys
40
Number of sells
-34
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mereo BioPharma Group plc - Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares (MREO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Northpond Ventures, LP 6.9% $136M 54.5M Michael P. Rubin Jun 4, 2025
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.62% $85M 43.6M Adage Capital Management, L.P. Dec 31, 2024
Rock Springs Capital Management LP 4.2% $65.2M 33.4M Rock Springs Capital Management LP Mar 31, 2025
Frazier Life Sciences Public Fund, L.P. 4.1% -20% $56.8M -$13.9M 32.4M -19.6% Frazier Life Sciences Public Fund, L.P. Jun 30, 2025
JANUS HENDERSON GROUP PLC 11.1% -22.9% $31M -$8.83M 17.7M -22.2% JANUS HENDERSON GROUP PLC Jun 30, 2025
Adage Capital Management, L.P. 1.07% $16.6M 8.5M Adage Capital Management, L.P. Mar 31, 2025

Institutional Holders of Mereo BioPharma Group plc - Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares (MREO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 9.18K $18.9K -$157 $2.06 1
2025 Q2 98.6M $267M -$28.8M $2.71 83
2025 Q1 111M $250M -$12.6M $2.25 87
2024 Q4 115M $403M +$29.7M $3.50 90
2024 Q3 106M $435M +$21.8M $4.11 76
2024 Q2 101M $362M +$59.9M $3.60 76
2024 Q1 84M $277M +$15.2M $3.30 77
2023 Q4 78.5M $181M +$12.8M $2.31 59
2023 Q3 69.9M $90.2M +$9.9M $1.29 52
2023 Q2 63.6M $84M +$2.51M $1.32 48
2023 Q1 60.8M $43M -$705K $0.71 56
2022 Q4 61.4M $46.1M -$7.73M $0.75 56
2022 Q3 68M $58.5M -$7.13M $0.86 56
2022 Q2 73.6M $82.5M -$16.9M $1.12 58
2022 Q1 88.9M $99.6M -$3.07M $1.12 55
2021 Q4 90.9M $145M -$12.2M $1.60 67
2021 Q3 87.5M $212M -$26.6M $2.42 57
2021 Q2 89.6M $284M -$2.19M $3.17 68
2021 Q1 90.2M $304M +$111M $3.37 65
2020 Q4 57.1M $205M +$140M $3.58 42
2020 Q3 14.3M $37.4M +$18M $2.62 20
2020 Q2 7.27M $22.3M +$12.8M $3.06 18
2020 Q1 1.4K $1K -$469K $0.71 1
2019 Q4 1.23M $4.05M -$2.32M $3.28 8
2019 Q3 1.76M $5.13M -$79.4K $2.94 12
2019 Q2 1.72M $4.19M +$4.19M $2.44 13